Adopting a combined targeted treatment approach in patients with BRAF-mutated melanoma has resulted in a dramatic increase in overall survival (OS); patients receiving combination therapy targeting BRAF and MEK have an OS of 25.9 months, whereas those receiving only chemotherapy have an OS of six months. The gene discussed is BRAF; the disease is melanoma.